MK-4646 Clinical Trials (2026): 2 Studies for Healthy & HIV Infection
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 MK-4646 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Healthy & HIV Infection) and 46 total planned enrollment. 1 MK-4646 clinical trial is actively recruiting. Most recent activity: NCT07042945 (Aug 2026).
MK-4646 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | Total |
|---|---|---|---|
| P1 | 1 | 1 | 2 |
Recruiting MK-4646 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07042945 | HIV-1MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) | P1 | HIV Infection | 28 | Jul 2025 |
MK-4646 clinical trials by indication
Healthy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07199452 | MK-4646-004 | P1 | completed | A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004) |
HIV Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07042945 | HIV-1 | P1 | recruiting | MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) |
All MK-4646 trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07042945 | HIV-1 | MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) | P1 | recruiting | 28 | Merck Sharp & Dohme LLC | Jul 2025 |
| NCT07199452 | MK-4646-004 | A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004) | P1 | completed | 18 | Merck Sharp & Dohme LLC | Oct 2025 |
MK-4646 clinical trials: frequently asked questions
- How many MK-4646 clinical trials are there?
- 2 MK-4646 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 1 is marked completed.
- Are MK-4646 clinical trials recruiting in 2026?
- Yes — 1 MK-4646 trial is actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is MK-4646 being studied for?
- MK-4646 is being studied for Healthy, HIV Infection. The trials are grouped by indication on this page.
- What phase is MK-4646 in?
- MK-4646 clinical trials span 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors MK-4646 clinical trials?
- The lead sponsor across the most MK-4646 trials is Merck Sharp & Dohme LLC. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming MK-4646as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: